AllurionMeds is designed to address a critical
demand from patients: The Weight Must Stay Off
Features Coach Iris, a first-of-its-kind
conversational AI behavioral agent for weight loss and maintenance,
trained using real-world experience in over 150,000 patients
Compounded GLP-1 program designed to provide
long-term behavioral change while addressing weight re-gain and
other negative side effects for patients
Expands Allurion’s presence to all 50 states,
helping to grow awareness of the mission to end obesity while
creating foothold for future product launches
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to
ending obesity, today announced the launch of AllurionMeds, a
unique offering to patients that combines affordable and accessible
weight loss medications with the company’s AI-native platform,
featuring Coach Iris, to promote long-term weight maintenance,
virtual access to dieticians and a connected smart scale measuring
not just weight but muscle and bone mass.
“Feedback from patients is clear; the weight must stay off. Our
platform was designed specifically to help patients lose weight and
keep it off,” said Dr. Shantanu Gaur, Founder and Chief Executive
Officer of Allurion. “AllurionMeds is built around safety, efficacy
and, importantly, efficiency. Without affordable medications for
weight loss and AI-powered behavior change, we risk bankrupting the
US healthcare system.”
The market opportunity for GLP-1s in the United States continues
to grow, with expectations that it exceeds $100 billion with 30
million total users by 2030.1 Recent studies are reporting,
however, that 30% of patients discontinue GLP-1 drugs in the first
month2 with significant muscle mass loss3. These issues, combined
with prices in excess of $1,300 per month4, will further the
obesity epidemic and lead to untenable expense in the US unless
access and support is improved for the millions of Americans living
with this disease.
Program will utilize AI to address most common GLP-1
concerns, including weight regain
The AllurionMeds GLP-1 program, with support from Coach Iris,
will address the most common concerns from patients looking to
begin a GLP-1 program. Patients in the program will receive access
to the Allurion Connected Scale and Allurion’s GLP-1 companion app.
The scale measures not only weight but also muscle and bone mass to
ensure that both the quantity and quality of weight loss is being
monitored. Previous studies have shown that Allurion’s scale, app
and lifestyle modification program in conjunction with the Allurion
Balloon have helped patients lose weight while actually gaining
muscle mass and helped them keep the weight off in the
long-run5,6.
“We are taking our decade-long experience of treating over
150,000 patients to launch an innovative, AI-native platform
designed to solve the problems GLP-1 users face and provide a
best-in-class experience,” said Dr. Gaur. “Real-world use of GLP-1s
has highlighted three critical issues: poor medication adherence
and wrap-around support, muscle and bone mass loss, and untenable
cost to the healthcare system. AllurionMeds leverages our existing
platform to address all three of these issues by providing 24/7
AI-powered coaching, monitoring of weight, muscle mass and bone
mass, and offering high quality and affordable compounded
semaglutide delivered at home.”
AllurionMeds partnered with FDA-registered pharmacies to
provide safe and financially accessible GLP-1 products available
across the US
Together with Coach Iris, patients will receive GLP-1 drugs that
are sourced from an FDA-registered 503b facility adherent to
Current Good Manufacturing Practice (CGMP) regulations. Every batch
has been tested for sterility and potency, among other things,
before release.
“Safety and ease of use were paramount to us as we were
designing AllurionMeds,” said Brian Conyer, Vice President of
Digital Health at Allurion. “After careful evaluation of multiple
partners, we selected pharmacies that met our high standards to
create an experience that is ‘always on’ through Coach Iris. In the
future, we intend to expand the types of GLP-1s available and also
offer brand-name versions to provide patients with as many options
as possible for their weight loss journey.”
Additionally, with the launch of AllurionMeds, the company has
expanded its product offerings to all 50 states in the United
Sates. Previously, the company had launched the Virtual Care Suite,
its B2B AI product, to obesity management clinics in the United
States.
“AllurionMeds further expands our presence in the United
States,” said Dr. Gaur. “I believe the relationships we are
creating with patients and providers in the United States could
benefit future product launches by creating a foothold in the
largest obesity market in the world.”
To access AllurionMeds, please visit
https://www.allurionmeds.com/.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight loss platform that features the Allurion Gastric Balloon,
the world’s first and only swallowable, Procedure-less™
intragastric balloon for weight loss, and offers access to the
Allurion Virtual Care Suite, including the Allurion Mobile App for
consumers, Allurion Insights for health care providers featuring
the Coach Iris AI Platform, and the Allurion Connected Scale. The
Allurion Virtual Care Suite is also available to providers
separately from the Allurion Program to help customize, monitor and
manage weight loss therapy for patients regardless of their
treatment plan: gastric balloon, surgical, medical or nutritional.
The Allurion Gastric Balloon is an investigational device in the
United States.
For more information about Allurion and the Allurion Virtual
Care Suite, please visit www.allurion.com.
Allurion is a trademark of Allurion Technologies, Inc. in the
United States and countries around the world.
Forward-Looking Statements
This press release may contain certain forward-looking
statements within the meaning of the U.S. federal and state
securities laws. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions and
include statements regarding the launch of the compounded GLP-1
program and the potential benefits and costs of such program,
including its ability to promote long-term weight maintenance,
address common GLP-1 issues and concerns, provide safe and
financially accessible products, and gain a foothold in the U.S.
for other products. Forward-looking statements are predictions,
projections and other statements about future events that reflect
the current beliefs and assumptions of Allurion’s management based
on information currently available to them and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future results or developments to differ materially from the
forward-looking statements in this communication, including but not
limited to (i) the ability of Allurion to obtain and maintain
regulatory approvals for and successfully commercialize its
program, including the Allurion Balloon, its VCS platform, and its
compounded GLP-1 program, in the United States and abroad, (ii) the
timing of, and results from, our clinical studies and trials and
submission of such results to regulatory authorities, (iii) the
evolution of the markets in which Allurion competes, (iv) the
ability of Allurion to defend its intellectual property, (v) the
impact of the COVID-19 pandemic, the Russia and Ukraine war, and
the conflict in the Middle East on Allurion’s business, (vi)
Allurion’s expectations regarding its market opportunities,
including those for the Allurion Program, its VCS platform, and its
compounded GLP-1 program (vii) the risk of economic downturns and a
changing regulatory landscape in the highly competitive industry in
which Allurion operates. The foregoing list of factors is not
exhaustive. You should carefully consider the foregoing factors and
the other risks and uncertainties described in the “Risk Factors”
section of Allurion’s Annual Report on Form 10-K filed on March 26,
2024 (as subsequently amended), Quarterly Report on Form 10-Q filed
on November 13, 2024, and other documents filed by Allurion from
time to time with the U.S. Securities and Exchange Commission.
These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Allurion assumes no obligation and does not intend
to update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Allurion
does not give any assurance that it will achieve its
expectations.
1
https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
2
https://www.bcbs.com/about-us/association-news/most-americans-stop-weight-loss-drugs-before-seeing-meaningful-benefit
3 Wilding et al. NEJM. 2021;384:989-1002. 4 Hernandez et al.
Obesity. 2024;32:472-475. 5 Dejeu et al. Clin. Pract.
2024;14:765-778. 6 Kosai et al. Obes Surg. 2024;34:3366-3371.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241125630472/en/
Global Media Cedric Damour PR Manager +33 7 84 21 02 20
cdamour@allurion.com
Investor Contact Mike Cavanaugh, Investor Relations ICR
Westwicke (617) 877-9641 mike.cavanaugh@westwicke.com
Allurion Technologies (NYSE:ALUR)
過去 株価チャート
から 11 2024 まで 12 2024
Allurion Technologies (NYSE:ALUR)
過去 株価チャート
から 12 2023 まで 12 2024
